News for Edgewise Therapeutics, Inc. (EWTX)

Summary Edgewise Therapeutics Inc (EWTX), a prominent biopharmaceutical company specializing in muscle diseases, has announced its participation in the Leerink

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Pa

Edgewise Therapeutics Inc (EWTX) exhibits a robust pipeline with lead product candidates sevasemten and EDG-7500 in advanced clinical trials.Despite a strong c

Significant Acquisition by PERCEPTIVE ADVISORS LLC (Trades, Portfolio) On February 13, 2025, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a notable addition

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

Significant Transaction by ORBIMED ADVISORS LLC (Trades, Portfolio) On December 31, 2024, ORBIMED ADVISORS LLC (Trades, Portfolio) executed a noteworthy transac

On December 31, 2024, Cormorant Asset Management, LP (Trades, Portfolio) made a significant move by acquiring an additional 823,219 shares of Praxis Precision M

Transaction Overview On December 31, 2024, Janus Henderson Group PLC made a strategic move by acquiring an additional 425,421 shares of Edgewise Therapeutics In

On February 5, 2025, Behrad Derakhshan, the Chief Business Officer of Edgewise Therapeutics Inc, executed a sale of 10,000 shares of the company. Following this

We recently compiled a list of the Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc (EWTX), a prominent biopharmaceutical company specializing in muscle diseases, announced that its President and CEO, Kevin Koch, Ph.D.

Edgewise Therapeutics chief scientific officer sells $2.74 million in stock

Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential and shareholder value. Read the full report on Seeking Alpha.

Edgewise Therapeutics chief development officer sells $882,914 in stock

On December 20, 2024, Orbimed Advisors LLC executed a strategic transaction involving Passage Bio Inc (PASG), a genetic medicines company. The firm reduced its

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Tesla, Inc. TSLA rose sharply during Monday's session after We...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Edgewise Therapeutics shares surge on positive trial results

Edgewise Therapeutics Inc (EWTX), a biopharmaceutical company specializing in muscle diseases, has announced positive topline results from its Phase 2 CANYON tr